Nobel prize winning economist Joseph Stiglitz says it's
Nobel prize winning economist Joseph Stiglitz says it's "absolutely wrong" for the U.S. to pass the trade deal known as the Trans-Pacific Partnership
It will only help big corporations, not American citizens, he says.
"The advocates of trade said it was going to benefit everyone. The evidence is it's benefited a few and left a lot behind," Stiglitz told CNN's Richard Quest on Quest Means Business Tuesday.
Both Donald Trump and Hillary Clinton are against TPP, a free trade agreement that President Obama has been pushing with 11 other Asian nations. China is not a part of the deal.
There's a chance Obama might try one last time to get Congress to pass TPP. Lawmakers typically come back to Washington for a few days after the presidential election. It's known as a "lame duck" session.
"I find that outrageous," says Stiglitz. "To rush it through in a lame-duck session, I think, is absolutely wrong."
Stiglitz is supporting Clinton and advising her on economic and trade policy. He says he's not against trade, but he thinks some deals America has in place have been a mistake.
"I would change NAFTA too," admits Stiglitz. He worked in Bill Clinton's administration and says NAFTA was inherited from the George H.W. Bush administration and no one wanted to tinker with it. "That was a big mistake."
While Trump has made fixing trade deals the centerpiece of his economic platform, Stiglitz says Trump goes too far. He's "basically a protectionist."
Related: China is crushing the U.S. in 'economic warfare'
Much like TPP, Stiglitz says NAFTA did not include enough protections for workers and intellectual property.
"The rhetoric that everyone was going to be better off was a lie," he says.
Stiglitz is currently promoting his new book, "The Euro: How A Common Currency Threatens The Future of Europe."
He argues the euro and the push for austerity have caused Europe to enter a prolonged economic slump.
1
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...
Continue Reading
The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...
Continue Reading
Bringing Artificial Intelligence to the Insurance Table Affordable American Insurance (AAI) is shaking things up in the insurance world with their new tool, Agency Gauge. Picture this: you're running an independent agency, neck-deep in data, and this AI-powered marvel swoops in and turns those confusing numbers into actionable business insights. It's like having a wise...
Continue Reading
A Peek into the Sale: What's on the Block? Get that coffee brewing and settle in, because we've got to unpack some interesting stuff happening with Chicago Scenic Studios. This isn't just any Craigslist decampment—Integra Asset Solutions is rolling out an online auction come October 27 that’ll have equipment-savvy investors’ ears perking up like they just snagged a...
Continue Reading
Breaking the Retirement Myth Retirement ain't just about sailing off into the sunset with a fat wallet. What happens when the honeymoon period of the "golden years" ends and you're left pacing the floorboards, unsure of what comes next? Enter Ama La Vida's fresh approach to retirement coaching, tackling the side of retirement that's rarely spoken about: identity,...
Continue Reading
Accreditations That Matter It's not every day a treatment facility pops its head up with credentials that weigh like a ton of bricks. New Chapter Recovery in New Jersey just snagged two heavy hitters: Joint Commission accreditation and LegitScript certification. These badges don’t just glimmer for show; they’re the market's assurance against empty promises—an...
Continue Reading
Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...
Continue Reading
Witch Hazel's Timeless Appeal You don’t get to celebrate over one and a half centuries of a product without doing something right. Dickinson Brands Inc. is throwing a bash worth noticing as they mark the sixth annual National Witch Hazel Day on October 21st. It’s a head-nod to the versatile witch hazel, a product that’s been part of New England's heritage since the...
Continue Reading
Collagen Solutions Front and Center First up, a little chat about collagen might be in order. For folks not tied into the science side, it sounds like a trendy wellness potion. But here comes GELITA at SupplySide Global 2026, showing it's the real McCoy. Nestled in Booth #4565, they're laying out a spread of next-gen collagen innovations aimed at everything from wound...
Continue Reading
Changing the Investment Game In a world where tech isn't the only kingmaker, distribution is the new play. Welcome the Nomada Fund, a fresh face on the investment scene that's swapping cash for exposure. Forget the traditional media-for-equity model that only old-timers still drool over—these guys are taking it up a notch with their new Distribution for Equity approach,...
Continue Reading
Top 5 Most Recently Viewed Articles
Highland Opportunities and Income Fund Announces Monthly Distribution The Highland Opportunities and Income Fund (NYSE: HFRO) has made an exciting announcement for its investors. The Fund is set to distribute $0.0385 per share for its common stock. This regular monthly distribution showcases the commitment of HFRO to return value to its shareholders. Understanding the...
Continue Reading
Invivyd Outlines Significant Findings on PEMGARDA™ at IDWeek 2024 Invivyd, Inc. (Nasdaq: IVVD), a dedicated biopharmaceutical enterprise, is set to present groundbreaking findings related to its investigational monoclonal antibody, pemivibart, at the much-anticipated IDWeek 2024 conference. Here, researchers and healthcare professionals will gather in Los Angeles to...
Continue Reading
AI's Remarkable Transformation of Software Engineering The world of software engineering is undergoing a significant transformation thanks to artificial intelligence (AI), redefining the roles engineers play and the skills necessary for success. A recent survey highlights that as AI continues to integrate into engineering practices, the fundamental aspects of this...
Continue Reading
5th Future Minerals Forum Successfully Concludes The recent edition of the Future Minerals Forum achieved impressive milestones with a remarkable attendance of 21,500 participants. This event marked a significant convergence of industry leaders, including investment executives, mining company heads, and experts from various technical fields around the globe. Key Agreement...
Continue Reading
Floreo's New Scientific Advisory Board Champions VR Therapy Floreo, a trailblazer in virtual reality (VR) therapy for neurodivergent individuals, proudly announces the formation of its inaugural scientific advisory board. The board will consist of six distinguished leaders from the realms of behavioral health research, clinical practice, and healthcare delivery, enhancing...
Continue Reading
